11 Capital Partners’s Edwards Lifesciences EW Stock Holding History

11 Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-94,995	Closed	-$6.58M	–	18
2023 Q3	$6.58M	Buy	94,995 +47,635	+101%	+$3.83M	3.06%	12
2023 Q2	$4.47M	Sell	47,360 -77,140	-62%	-$6.7M	1.86%	15
2023 Q1	$10.3M	Sell	124,500 -15,000	-11%	-$1.18M	5.08%	9
2022 Q4	$10.4M	Buy	+139,500	New	+$10.8M	6.56%	8
2021 Q3	–	Sell	-153,684	Closed	-$15.9M	–	23
2021 Q2	$15.9M	Sell	153,684 -115,222	-43%	-$10.9M	3.2%	17
2021 Q1	$22.5M	Buy	268,906 +62,923	+31%	+$5.32M	5.12%	8
2020 Q4	$18.8M	Buy	+205,983	New	+$17.1M	5.52%	9

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

11 Capital Partners's EW Position: Q4 2023 in Review

11 Capital Partners sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 94,995 shares — an estimated $6.58M sold.

11 Capital Partners first reported a position in EW in Q4 2020 and held it in 7 quarters. The position peaked at $22.5M in Q1 2021. 1,245 funds tracked by Wall St. Rank hold EW as of Q4 2023.

11 Capital Partners reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
11 Capital Partners sold 94,995 Edwards Lifesciences shares in Q4 2023, an estimated $6.58M.
11 Capital Partners first reported a position in Edwards Lifesciences in Q4 2020 and held it in 7 quarters.
11 Capital Partners's Edwards Lifesciences position peaked at $22.5M in Q1 2021.
1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.

Based on 11 Capital Partners's 13F filing for Q4 2023, filed 13 Feb 2024.